Oral GLP-1 Drugs Market - Industry Dynamics, Market Size, and Opportunity Forecast to 2035

Oral GLP-1 Drugs Market: By Drug Type (Oral Peptide GLP-1 Agonists, Small-Molecule Non-Peptide GLP-1 Agonists); Molecule (Semaglutide (Oral), Orforglipron, Danuglipron, Other Emerging Candidates); Indication (Type 2 Diabetes, Obesity / Weight Management, Cardiometabolic / NASH, Others); Patient Population (Diabetic, Obese / Overweight, Cardiovascular-Risk); Distribution Channel (Hospital & Specialty Pharmacies, Retail Pharmacies, Online Pharmacies); End User (Hospitals & Clinics, Homecare, Specialty Centers)—Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026–2035

The global oral GLP-1 drugs market is estimated at USD 6.5 billion in 2025 and is projected to reach USD 32.1 billion by 2035, growing at a CAGR of 24.8% over the forecast period 2025–2035. Read More

We Are Trusted By These Great Companies!

• Last Updated: 15-Jun-2026  |  Format:  |  Report ID: AA06261830